Society

Society for Laboratory Automation and Screening (SLAS) Selects CytoTronics’ Pixel System for 2024 New Product Award

Retrieved on: 
Tuesday, March 5, 2024

CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).

Key Points: 
  • CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Award selection was announced at the SLAS2024 International Conference and Exhibition in Boston, MA on February 6th, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240305158077/en/
    CytoTronics' Pixel™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Front-runners are interviewed on-site at the conference by a panel of industry veterans with deep expertise in laboratory automation and screening techniques to determine final award recipients.

SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL

Retrieved on: 
Friday, March 1, 2024

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Societal CDMO, Inc. (NasdaqCM: SCTL) to CoreRx, Inc.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Societal CDMO, Inc. (NasdaqCM: SCTL) to CoreRx, Inc.
  • Under the terms of the proposed transaction, shareholders of Societal will receive $1.10 in cash for each share of Societal that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study

Retrieved on: 
Thursday, February 29, 2024

The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).

Key Points: 
  • The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).
  • The PTAB1 Post-Market Study evaluates the DETOUR System's performance in patients with very long (TASC D) SFA lesions.
  • The study plans to enroll up to 450 subjects, with a focus on including at least 200 women and also features an imaging sub study.
  • “The initiation of the PTAB1 Post-Market Study represents a pivotal moment in our ongoing commitment to advance the treatment of complex peripheral arterial disease.

AI Technology 2024: Dynamic Predictions for Future Market Success in Generative AI - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024

In the realm of technological progress, artificial intelligence (AI) has emerged as a transformative force with the potential to reshape industries of the future.

Key Points: 
  • In the realm of technological progress, artificial intelligence (AI) has emerged as a transformative force with the potential to reshape industries of the future.
  • 89% of enterprises believe Generative AI technology will be a disruptive technology for enterprises to create strategic market differentiation.
  • As AI evolves, its profound impact on businesses, economies, and societies makes it a pivotal technology in the digital landscape of an enterprise.
  • These predictions offer ample growth opportunities for vendors and ecosystem players to capitalize and emerge at the forefront of the AI industry.

Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024

Retrieved on: 
Wednesday, February 28, 2024

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024.
  • The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease.
  • Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications.
  • "The data being showcased highlight the critical role circulating tumor HPV DNA assessment can play in shaping patient care strategies.

Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

Key Points: 
  • Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.
  • For the first quarter of 2024, software revenue is expected to range from $33 million to $35 million.
  • “We had a very strong year in 2023, with significant growth in our software and drug discovery revenue and substantial progress in our proprietary pipeline and at our co-founded companies.
  • Schrödinger will host a conference call to discuss its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, at 4:30 p.m.

SCTL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Societal CDMO, Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, February 29, 2024

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Societal CDMO, Inc. (NASDAQ: SCTL) to CoreRx, Inc. for $1.10 per share in cash is fair to Societal CDMO shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Societal CDMO, Inc. (NASDAQ: SCTL) to CoreRx, Inc. for $1.10 per share in cash is fair to Societal CDMO shareholders.
  • The investigation concerns whether Societal CDMO and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Societal CDMO shareholders; (2) determine whether CoreRx is underpaying for Societal CDMO; and (3) disclose all material information necessary for Societal CDMO shareholders to adequately assess and value the merger consideration.
  • On behalf of Societal CDMO shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 to the NDA.
  • In September 2023, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for imetelstat in the same proposed indication as the NDA.
  • Geron will host a conference call at 8:00 am ET on Wednesday, February 28, 2024, to discuss business updates and fourth quarter and full year 2023 financial results.

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
Tuesday, February 27, 2024

The FDA grants Priority Review to investigational therapies that, if approved, may offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.

Key Points: 
  • The FDA grants Priority Review to investigational therapies that, if approved, may offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.
  • “The acceptance of the epcoritamab application for Priority Review marks an important milestone toward potentially providing a new treatment option to patients affected by R/R follicular lymphoma.
  • The FDA previously granted Breakthrough Therapy Designation (BTD) to epcoritamab for the treatment of adult patients with R/R FL after two or more lines of systemic therapy.
  • The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

Retrieved on: 
Tuesday, February 27, 2024

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy.
  • The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024.
  • Axatilimab is being developed by Incyte and Syndax Pharmaceuticals (Nasdaq:SNDX) as part of an exclusive worldwide co-development and co-commercialization license agreement.
  • “Axatilimab’s novel mechanism offers a differentiated treatment approach which may help patients suffering from this devastating disease.